This has been an amazing year for stocks. From the end of 2023 through Nov. 12, the benchmark S&P 500 index climbed 25% ...
And biotech is progressing in the right direction ... A potential P/E multiple re-rating coupled with good growth prospects ...
Aurobindo Pharma’s revenue was in-line with our estimates ... We revise our rating to “BUY” from “ACCUMULATE” based on the ...
The clinical-stage biopharmaceutical company named Julie Eastland as chief executive officer, president and director. She succeeds Kimberly Blackwell, who will remain as a strategic advisor to the ...
Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...
Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...
Ruiz covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Cytokinetics, and Lantheus. ARS Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target ...
The health-tech industry’s long-term growth is fueled by the growing need for cutting-edge technologies to address critical ...
If all continues to go well with its development, a new rocket should open up new customer segments for the company.
November 12, 2024 13:03 Stock market live today: Marksans Pharma Q2 net profit soars to ₹63.20 crore, shares rise 1.89% ...